CoChat

Continuous Positive Airway Pressure for Central Sleep Apnea and Heart Failure

Open access

The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure trial tested the hypothesis that continuous positive airway pressure (CPAP) would improve the survival rate without heart transplantation of patients who have central sleep apnea and heart failure. METHODS: After medical therapy was optimized, 258 patients who had heart failure (mean age [+/-SD], 63+/-10 years; ejection fraction, 24.5+/-7.7 percent) and central sleep apnea (number of episodes of apnea and hypopnea per hour of sleep, 40+/-16) were randomly assigned to receive CPAP (128 patients) or no CPAP (130 patients) and were followed for a mean of two years. During follow-up, sleep studies were conducted and measurements of the ejection fraction, exercise capacity, quality of life, and neurohormones were obtained. RESULTS: Three months after undergoing randomization, the CPAP group, as compared with the control group, had greater reductions in the frequency of episodes of apnea and hypopnea (-21+/-16 vs. -2+/-18 per hour, P<0.001) and in norepinephrine levels (-1.03+/-1.84 vs. 0.02+/-0.99 nmol per liter, P=0.009), and greater increases in the mean nocturnal oxygen saturation (1.6+/-2.8 percent vs. 0.4+/-2.5 percent, P<0.001), ejection fraction (2.2+/-5.4 percent vs. 0.4+/-5.3 percent, P=0.02), and the distance walked in six minutes (20.0+/-55 vs. -0.8+/-64.8 m, P=0.016). There were no differences between the control group and the CPAP group in the number of hospitalizations, quality of life, or atrial natriuretic peptide levels. An early divergence in survival rates without heart transplantation favored the control group, but after 18 months the divergence favored the CPAP group, yet the overall event rates (death and heart transplantation) did not differ (32 vs. 32 events, respectively; P=0.54). CONCLUSIONS: Although CPAP attenuated central sleep apnea, improved nocturnal oxygenation, increased the ejection fraction, lowered norepinephrine levels, and increased the distance walked in six minutes, it did not affect survival. Our data do not support the use of CPAP to extend life in patients who have central sleep apnea and heart failure.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa051001

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Bradley TD, 2001, Can J Cardiol, 17, 677
  2. Staats BA, 1984, Am Rev Respir Dis, 130, 59
  3. Johnstone DE, 1994, Can J Cardiol, 10, 613
  4. 10.1172/jci21748 · doi:10.1172/jci21748 · Paper page

Cited by

See all 1,189

Metadata

Authors
Bradley, T. D., Logan, A. G., Kimoff, R. J., Sériès, F., Morrison, D., Ferguson, K., Belenkie, I., Pfeifer, M., Fleetham, J., Hanly, P., Smilovitch, M., Tomlinson, G., & Floras, J. S.
Affiliations
  • University of Toronto (CA)
  • McGill University (CA)
  • Université Laval (CA)
  • Dalhousie University (CA)
  • Western University (CA)
  • University of Calgary (CA)
  • University of Regensburg (DE)
  • University of British Columbia (CA)
Venue
New England Journal of Medicine
Published
2005-11-10
Volume
353
Issue
19
Pages
2025-2033
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2130637800
Cited by
1,189
References
45
Citations by year
2026: 16 · 2025: 31 · 2024: 33 · 2023: 47 · 2022: 45 · 2021: 51 · 2020: 40 · 2019: 55 · 2018: 50 · 2017: 70 · 2016: 87 · 2015: 68 · 2014: 44 · 2013: 67 · 2012: 62
FWCI
45.16
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
continuous positive airway pressure, central sleep apnea, heart failure, nocturnal oxygen saturation, norepinephrine, ejection fraction, exercise capacity, neurohormones, atrial natriuretic peptide, quality of life, heart transplantation, sleep-disordered breathing, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
MeSH terms
Aged, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Norepinephrine, Stroke Volume, Survival Rate, Proportional Hazards Models, Heart Transplantation, Treatment Outcome, Exercise Tolerance, Sleep Apnea, Central, Continuous Positive Airway Pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.